Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

(2017) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Diagnostics of HER2 Positivity in Gastroesophageal Adenocarcinoma

(2015) Timco Koopman et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

(2015) Sylvie Lorenzen et al.   EUROPEAN JOURNAL OF CANCER

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

(2015) Zachary C. Dobbin et al.   Oncotarget

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

(2014) Y J Liu et al.   BRITISH JOURNAL OF CANCER

Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer

(2014) Z. Zhang et al.   CLINICAL CANCER RESEARCH

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

(2014) R. Duchnowska et al.   CLINICAL CANCER RESEARCH

Organoid cultures for the analysis of cancer phenotypes

(2014) Norman Sachs et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

(2014) Eric Van Cutsem et al.   Gastric Cancer

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

(2014) Sang Yun Ha et al.   INTERNATIONAL JOURNAL OF CANCER

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

(2014) Taroh Satoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis

(2014) Jamie M J Weaver et al.   NATURE GENETICS

High-Definition Reconstruction of Clonal Composition in Cancer

(2014) Andrej Fischer et al.   Cell Reports

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity

(2013) Austin M Dulak et al.   NATURE GENETICS

A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers

(2013) Jeeyun Lee et al.   PLoS One

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

(2013) Manish A. Shah et al.   PLoS One

The Life History of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

A systematic approach to therapeutic target selection in oesophago-gastric cancer

(2012) Anna L Paterson et al.   GUT

Early HER2 dysregulation in gastric and oesophageal carcinogenesis

(2012) Matteo Fassan et al.   HISTOPATHOLOGY

Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis

(2012) Anna L Paterson et al.   JOURNAL OF PATHOLOGY

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

(2011) S. Iqbal et al.   ANNALS OF ONCOLOGY

SomaticSniper: identification of somatic point mutations in whole genome sequencing data

(2011) David E. Larson et al.   BIOINFORMATICS

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

(2010) Z. A. Wainberg et al.   CLINICAL CANCER RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Allele-specific copy number analysis of tumors

(2010) P. Van Loo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer

(2009) William H. Allum et al.   JOURNAL OF CLINICAL ONCOLOGY

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

(2008) D. L. Shattuck et al.   CANCER RESEARCH

hCGβ expression by cervical squamous carcinoma –in vivohistological association with tumour invasion and apoptosis

(2008) D Li et al.   HISTOPATHOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE